TH59456A3 - Streptococcus suis vaccine and diagnostic tests - Google Patents

Abstract

DC60 (05/10/55) Invention is associated with infection. Streptococcus suis of pigs, a vaccine aimed at Those infections and tests for diagnosing infections Streptococcus suis This invention yielded either the extracted nucleic acid or the processed nucleic acid compound. The Chinese capsule group code of Streptococcus suis, or Chinese, or Chinese fragments derived from it. Moreover, the invention provided a nucleic acid probe or primer that made the detection. Streptococcus suis that is specific to serotypes can occur. Invention also provides antigens. Streptococcus suis and its derivative vaccines are involved in infection. Streptococcus suis of pigs, a vaccine aimed at Those infections and tests for diagnosing infections Streptococcus suis This invention yielded either the extracted nucleic acid or the processed nucleic acid compound. The Chinese capsule group code of Streptococcus suis, or Chinese, or Chinese fragments derived from it. Moreover, the invention provided a nucleic acid probe or primer that made the detection. Streptococcus suis that is specific to serotypes can occur. Invention also provides antigens. Streptococcus suis and its proprietary vaccine, patent medicine

Claims (9)

Disclaimer (all) that will not appear on the advertisement page: 1. Elements that include The knockout mutation of Streptococcus suis cytotype 2, the inactivated mutation. It is in the capsular polysaccharide (cps) gene group as specified in SEQ ID NO: 9, in which the inactivated mutation is in the cpsB gene that processes the cpsB protein code as required. Listed in SEQ ID NO: 13, the cpsE gene that processes the cpsE protein code as specified in SEQ ID NO: 16, or the cpsF gene that processes the cpsF protein code as specified in SEQ ID NO: 17, or its aggregate. Those genes, whose mutations are inactivated Induces deficiency in cell characterization, and Carrier or pharmaceutical additive; 2. Nucleic acid according to claim 1, coding the central region specific to the serotypes of Streptococcus suis should be That code at least one type of enzyme or parts of it 3. Nucleic acid according to claim 1 or 2 that is hybridized to the nucleic acid that is Chinese code derivative from. China Capsular Group of Streptococcus suis serotypes 1, 2 or 9 4. Isolated nucleic acids. Or Nucleic acid recombinant, Chinese group code, Streptococcus suis serotypes 2, or China, or derivative Chinese parts from it. That should be as indicated in Figure 3. 5. Isolated nucleic acids. Or Nucleic acid recombinant, Chinese group code, Streptococcus suis serotypes 1, or China, or derivative Chinese parts from it. That should, as indicated in Figure 4. 6. Separated nucleic acids. Or nucleic acid recombinant group code, Gene, the encapsulation of Streptococcus suis, serotypes 9, or China, or the derivative Chinese parts from it. As indicated in Figure 5. 7. Nucleic acid probe or nucleic acid derivative primer according to one of Claims 1 to 6 that makes detection Species-specific streptococcus suis or serotypes can occur 8. Probe or primer according to claim 7, given with at least one reporter molecule. 9. A diagnostic test consisting of a probe or primer according to claim 7 or 8 1 0. Protein or its parts that have been coded by nucleic acid in accordance with Clause 8. Any of claims 1 to 6 1 1. The protein or part according to claim 10 that can be synthesized S. biological suis 1 2. A method for producing capsular antigens of Streptococcus suis consisting of protein or Fragments according to claim 11 1 3.Capsular antigens of Streptococcus suis can be obtained by means of claim 12 1 4. Vaccines containing antigens in claim 13 and later containing carriers or Suitable synergistic 1 5. Mutants Streptococcus suis recombinant supplied with the modified Chinese encapsulation group 1 6. The recombinant microbiome comprising the Chinese encapsulation group of At least one part of Streptococcus suis 7. Pre-combinant microorganisms according to claim 16 containing lactic acid bacterium 1. 8. Vaccines containing mutant strains. According to claim 15 Or microorganisms according to claim 16 or 17 1 9. Vaccines according to claim 18 that includes mutants. Streptococcus That cannot be displayed Characteristics of the capsule 2 0. Vaccine according to claim 19 where the mutant Streptococcus Such a derivative by the supposed recombination technique is by homologous recombination type 2. 1. Vaccine according to claim 19 or 20, where the mutant Can survive on immune-competent host 2. 2. Vaccine according to claim 21 where the mutant survives at least 5 days, preferably at least 8 days in the host cell 2. 3. Vaccines pursuant to claims 19 through 22, including mutants capable of Characterizes the virulence factor of Streptococcus. Or antigenic determinant 2 4. Vaccines according to any of claims 19 through 23, including mutants capable of Characterization of proteins that are not of Streptococcus 2 5. Vaccine according to claim 24, where proteins other than Streptococcus Has been approved from pathogens 2 6. Methods for the control or elimination of streptococcal disease in a population composed of vaccinating subject in such populations. With a vaccine according to any of the terms 18 through 25 2 7.Methods for controlling or eliminating streptococcal disease that include Sample test obtained Collected from at least one subject in some or all of the populations received. Vaccine according to any of the claims 19 to 25 for the presence of streptococcal strains in capsule 2. 8.Methods for controlling or eliminating streptococcal disease that include Sample test obtained Collected from at least one subject in some or all of the populations received. Vaccine pursuant to any of Articles 19 to 25 for the presence of antibodies specific to the capsule that Aiming Against Streptococcal 2 Strains 9. Methods for the control or eradication of streptococcal disease in a population composed of subject selection in those populations vaccinated according to one of the claims made by 19 to 25 and testing of samples collected from at least one subject in the population. For having streptococcal strains that enter the capsule And / or for having Capsule specific antibodies aimed at neutralizing streptococcal strains.